专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20100124747A1 COMPOSITIONS AND METHODS FOR DIAGNOSIS OR PROGNOSIS OF TESTICULAR CANCER 审中-公开
标题翻译：用于诊断或预防特发性癌症的组合物和方法
公开(公告)号：US20100124747A1
公开(公告)日：2010-05-20
申请号：US12611309
申请日：2009-11-03
申请人： Peter W. Laird , Sahar Houshdaran , Victoria Cortessis , Kimberly D. Siegmund , Rebecca Z. Sokol
发明人： Peter W. Laird , Sahar Houshdaran , Victoria Cortessis , Kimberly D. Siegmund , Rebecca Z. Sokol
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/136 , C12Q2600/154
摘要： Provided are compositions and methods for diagnosis or prognosis of testicular or male germ-cell derived cancer, comprising: obtaining sperm DNA from a test subject; determining the methylation status of at least one CpG dinucleotide sequence of at least one gene sequence selected from HRAS, NTF3, MT1A, PAX8, DIRAS3, PLAGL1, SFN, SAT2CHRM1, MEST, RNR1, CYP27B1 and ICAM1; and thereby determining or diagnosing testicular or male germ-cell derived cancer. Provided are compositions and methods for identifying agents that cause testicular or male germ-cell derived cancer, comprising: obtaining human ES-cell derived primordial germ cells; contacting the germ cells or descendants thereof, with a test agent; culturing the contacted cells; determining, using a genomic DNA of the sample, the methylation status of at least one CpG dinucleotide sequence of at least one gene sequence selected from the above group; and identifying at least one test agent that causes testicular or male germ-cell derived cancer.
摘要翻译：提供了用于睾丸或雄性生殖细胞衍生癌症的诊断或预后的组合物和方法，包括：从测试受试者获得精子DNA; 确定至少一个选自HRAS，NTF3，MT1A，PAX8，DIRAS3，PLAGL1，SFN，SAT2CHRM1，MEST，RNR1，CYP27B1和ICAM1的基因序列的至少一个CpG二核苷酸序列的甲基化状态; 从而确定或诊断睾丸或雄性生殖细胞衍生的癌症。提供用于鉴定导致睾丸或雄性生殖细胞衍生的癌症的药剂的组合物和方法，包括：获得人ES细胞衍生的原始生殖细胞; 使生殖细胞或其后代与测试剂接触; 培养接触细胞; 使用所述样品的基因组DNA确定至少一种选自上述基团的至少一个基因序列的至少一个CpG二核苷酸序列的甲基化状态; 并鉴定至少一种导致睾丸或雄性生殖细胞衍生的癌症的测试试剂。

2. 发明申请

US20120219946A1 DNA METHYLATION MARKERS ASSOCIATED WITH THE CPG ISLAND METHYLATOR PHENOTYPE (CIMP) IN HUMAN COLORECTAL CANCER 审中-公开
标题翻译：与人类癌症中的CPG岛状甲基化合物（CIMP）相关的DNA甲基化标记
公开(公告)号：US20120219946A1
公开(公告)日：2012-08-30
申请号：US13366192
申请日：2012-02-03
申请人： Peter W. Laird , Kimberly D. Siegmund , Mihaela Campan , Daniel J. Weisenberger , Tiffany I. Long
发明人： Peter W. Laird , Kimberly D. Siegmund , Mihaela Campan , Daniel J. Weisenberger , Tiffany I. Long
IPC分类号： C12Q1/68 , C07H21/04 , G01N33/574
CPC分类号： C12Q1/6886 , C12Q2600/112 , C12Q2600/154 , C12Q2600/156 , C12Q2600/158
摘要： Particular aspects confirm the existence of a CpG island methylator phenotype (CIMP) in colorectal cancer, and provide novel validated DNA methylation markers associated with CIMP. Additional aspects provide novel methods and compositions for: determining CIMP status in colorectal cancers, determining the relationship between CIMP status and other molecular features of the cancers (e.g., BRAF mutation, KRAS mutation and MSI status); determining the relationship between CIMP status and other variables (e.g., age, sex, tumor location, family history, race, country of origin, tumor characteristics (including, tumor type, tumor grade, invasive margin characteristics, lymphocyte infiltration characteristics, direct spread, lymph node spread, venous spread and type of residual adjacent polyp, if present)); and determining, between subgroups defined by CIMP status and BRAF mutations, effects of selected risk factors (e.g., body mass index, smoking history, alcohol intake, dietary folate intake, folate metabolic enzyme polymorphisms and history of hormonal use).
摘要翻译：特异性方面证实了结肠直肠癌中CpG岛甲基化表型（CIMP）的存在，并提供与CIMP相关的新的有效DNA甲基化标记。另外的方面提供了新的方法和组合物：确定结肠直肠癌中的CIMP状态，确定CIMP状态与癌症的其它分子特征（例如BRAF突变，KRAS突变和MSI状态）之间的关系; 确定CIMP状态与其他变量（如年龄，性别，肿瘤位置，家族史，种族，起源国家，肿瘤特征（包括肿瘤类型，肿瘤等级，浸润性边缘特征，淋巴细胞浸润特征，直接传播，淋巴结扩散，静脉扩散和残留相邻息肉的类型，如果存在））; 并确定由CIMP状态和BRAF突变所定义的亚组之间，选择的风险因素（例如体重指数，吸烟史，酒精摄入，饮食叶酸摄入，叶酸代谢酶多态性和激素使用史）的影响。

3. 发明申请

US20090053706A1 DNA METHYLATION MARKERS ASSOCIATED WITH THE CPG ISLAND METHYLATOR PHENOTYPE (CIMP) IN HUMAN COLORECTAL CANCER 失效
标题翻译：与人类癌症中的CPG岛状甲基化合物（CIMP）相关的DNA甲基化标记
公开(公告)号：US20090053706A1
公开(公告)日：2009-02-26
申请号：US11913535
申请日：2006-05-02
申请人： Peter W. Laird , KImberly D. Siegmund , Mihaela Campan , Daniel J. Weisenberg , Tiffany I. Long
发明人： Peter W. Laird , KImberly D. Siegmund , Mihaela Campan , Daniel J. Weisenberg , Tiffany I. Long
IPC分类号： C12Q1/68 , C12Q1/02 , G01N33/53 , C07H21/00
CPC分类号： C12Q1/6886 , C12Q2600/112 , C12Q2600/154 , C12Q2600/156 , C12Q2600/158
摘要： Particular aspects confirm the existence of a CpG island methylator phenotype (CIMP) in colorectal cancer, and provide novel validated DNA methylation markers associated with CIMP. Additional aspects provide novel methods and compositions for: determining CIMP status in colorectal cancers, determining the relationship between CIMP status and other molecular features of the cancers (e.g., BRAF mutation, KRAS mutation and MSI status); determining the relationship between CIMP status and other variables (e.g., age, sex, tumor location, family history, race, country of origin, tumor characteristics (including, tumor type, tumor grade, invasive margin characteristics, lymphocyte infiltration characteristics, direct spread, lymph node spread, venous spread and type of residual adjacent polyp, if present)); and determining, between subgroups defined by CIMP status and BRAF mutations, effects of selected risk factors (e.g., body mass index, smoking history, alcohol intake, dietary folate intake, folate metabolic enzyme polymorphisms and history of hormonal use).
摘要翻译：特异性方面证实了结肠直肠癌中CpG岛甲基化表型（CIMP）的存在，并提供与CIMP相关的新的有效DNA甲基化标记。另外的方面提供了新的方法和组合物：确定结肠直肠癌中的CIMP状态，确定CIMP状态与癌症的其它分子特征（例如BRAF突变，KRAS突变和MSI状态）之间的关系; 确定CIMP状态与其他变量（如年龄，性别，肿瘤位置，家族史，种族，起源国家，肿瘤特征（包括肿瘤类型，肿瘤等级，浸润性边缘特征，淋巴细胞浸润特征，直接传播，淋巴结扩散，静脉扩散和残留相邻息肉的类型，如果存在））; 并确定由CIMP状态和BRAF突变所定义的亚组之间，选择的风险因素（例如体重指数，吸烟史，酒精摄入，饮食叶酸摄入，叶酸代谢酶多态性和激素使用史）的影响。

4. 发明授权

US08110361B2 DNA methylation markers associated with the CpG island methylator phenotype (CIMP) in human colorectal cancer 失效
标题翻译：与人结肠直肠癌中CpG岛甲基化表型（CIMP）相关的DNA甲基化标记
公开(公告)号：US08110361B2
公开(公告)日：2012-02-07
申请号：US11913535
申请日：2006-05-02
申请人： Peter W. Laird , Kimberly D. Siegmund , Mihaela Campan , Daniel J. Weisenberger , Tiffany I. Long
发明人： Peter W. Laird , Kimberly D. Siegmund , Mihaela Campan , Daniel J. Weisenberger , Tiffany I. Long
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/112 , C12Q2600/154 , C12Q2600/156 , C12Q2600/158
摘要： Particular aspects confirm the existence of a CpG island methylator phenotype (CIMP) in colorectal cancer, and provide novel validated DNA methylation markers associated with CIMP. Additional aspects provide novel methods and compositions for: determining CIMP status in colorectal cancers, determining the relationship between CIMP status and other molecular features of the cancers (e.g., BRAF mutation, KRAS mutation and MSI status); determining the relationship between CIMP status and other variables (e.g., age, sex, tumor location, family history, race, country of origin, tumor characteristics (including, tumor type, tumor grade, invasive margin characteristics, lymphocyte infiltration characteristics, direct spread, lymph node spread, venous spread and type of residual adjacent polyp, if present)); and determining, between subgroups defined by CIMP status and BRAF mutations, effects of selected risk factors (e.g., body mass index, smoking history, alcohol intake, dietary folate intake, folate metabolic enzyme polymorphisms and history of hormonal use).
摘要翻译：特异性方面证实了结肠直肠癌中CpG岛甲基化表型（CIMP）的存在，并提供与CIMP相关的新的有效DNA甲基化标记。另外的方面提供了新的方法和组合物：确定结肠直肠癌中的CIMP状态，确定CIMP状态与癌症的其它分子特征（例如BRAF突变，KRAS突变和MSI状态）之间的关系; 确定CIMP状态与其他变量（如年龄，性别，肿瘤位置，家族史，种族，起源国家，肿瘤特征（包括肿瘤类型，肿瘤等级，浸润性边缘特征，淋巴细胞浸润特征，直接传播，淋巴结扩散，静脉扩散和残留相邻息肉的类型，如果存在））; 并确定由CIMP状态和BRAF突变所定义的亚组之间，选择的风险因素（例如体重指数，吸烟史，酒精摄入，饮食叶酸摄入，叶酸代谢酶多态性和激素使用史）的影响。

5. 发明申请

US20090246771A1 COMPOSITIONS AND METHODS COMPRISING BIOMARKERS OF SPERM QUALITY, SEMEN QUALITY AND FERTILITY 审中-公开
标题翻译：组合物和方法包括生物标志物质量，质量和品质
公开(公告)号：US20090246771A1
公开(公告)日：2009-10-01
申请号：US12264048
申请日：2008-11-03
申请人： Peter W. Laird , Sahar Houshdaran , Victoria Cortessis , Kimberly D. Siegmund , Rebecca Z. Sokol
发明人： Peter W. Laird , Sahar Houshdaran , Victoria Cortessis , Kimberly D. Siegmund , Rebecca Z. Sokol
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12Q2523/125 , C12Q2600/136 , C12Q2600/154
摘要： Provided are compositions and methods for determining or diagnosing abnormal sperm or fertility, comprising: obtaining sperm DNA from a test subject; determining the methylation status of at least one CpG dinucleotide sequence of at least one gene sequence selected from HRAS, NTF3, MT1A, PAX8, DIRAS3, PLAGL1, SFN, SAT2CHRM1, MEST, RNR1, CYP27B1 and ICAM1; and thereby determining or diagnosing abnormal sperm or fertility. Provided are compositions and methods for identifying agents that cause spermatogenic deficits or abnormal sperm fertility, comprising: obtaining human ES-cell derived primordial germ cells; contacting the germ cells or descendants thereof, with a test agent; culturing the contacted cells; determining, using a genomic DNA of the sample, the methylation status of at least one CpG dinucleotide sequence of at least one gene sequence selected from the above group; and identifying at least one test agent that causes at least one of spermatogenic deficits, abnormal sperm, and abnormal fertility.
摘要翻译：提供了用于确定或诊断异常精子或生殖力的组合物和方法，包括：从测试对象获得精子DNA; 确定至少一个选自HRAS，NTF3，MT1A，PAX8，DIRAS3，PLAGL1，SFN，SAT2CHRM1，MEST，RNR1，CYP27B1和ICAM1的基因序列的至少一个CpG二核苷酸序列的甲基化状态; 从而确定或诊断异常精子或生育能力。提供了用于鉴定引起精子发生缺陷或异常精子生殖力的药剂的组合物和方法，其包括：获得人ES细胞衍生的原始生殖细胞; 使生殖细胞或其后代与测试剂接触; 培养接触细胞; 使用所述样品的基因组DNA确定至少一种选自上述基团的至少一个基因序列的至少一个CpG二核苷酸序列的甲基化状态; 并鉴定至少一种导致精子发生缺陷，异常精子和异常生育力中的至少一种的试剂。

6. 发明申请

US20090136921A1 Association of Breast Cancer DNA Methylation Profiles with Hormone Receptor Status and Response to Tamoxifen 有权
标题翻译：乳腺癌DNA甲基化配置文件与激素受体状态和他莫昔芬反应的关系
公开(公告)号：US20090136921A1
公开(公告)日：2009-05-28
申请号：US11628390
申请日：2005-06-01
申请人： Martin Widschwendter , Kimberly D. Siegmund , Peter A. Jones , Peter W. Laird
发明人： Martin Widschwendter , Kimberly D. Siegmund , Peter A. Jones , Peter W. Laird
IPC分类号： C12Q1/68 , C40B30/00
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/118 , C12Q2600/154
摘要： Particular embodiments provide novel and clinically useful DNA methylation predictors of hormone receptor status, and predictors of response to endocrine (e.g., hormonal) and non-endocrine breast cancer therapy. The ESR1 gene, encoding the estrogen receptor (ER) alpha proved to be the preferred predictor of progesterone receptor (PR) status, while methylation of the PGR gene, encoding PR, was the preferred predictor of ER status. ESR1 methylation outperformed hormone receptor status as a predictor of clinical response in patients treated with antiestroges (e.g., tamoxifen), while promoter methylation of the CYP1B1 gene, encoding a tamoxifen and estradiol metabolizing cytochrome P450, predicted response differentially in tamoxifen-treated and non-treated patients. High levels of promoter methylation of the ARHI gene, encoding a RAS-related small G-protein, were shown to be preferred predictors of better survival in patients who had not received tamoxifen therapy.
摘要翻译：具体实施方案提供了激素受体状态的新型和临床有用的DNA甲基化预测因子，以及对内分泌（例如激素）和非内分泌乳腺癌治疗的预测因子。编码雌激素受体（ER）α的ESR1基因被证明是孕酮受体（PR）状态的优选预测因子，而编码PR的PGR基因的甲基化是ER状态的优选预测因子。 ESR1甲基化表现优于激素受体状态，作为用抗静脉药物治疗的患者（如他莫昔芬）的临床反应预测因子，而CYP1B1基因的启动子甲基化，编码他莫昔芬和雌二醇代谢细胞色素P450，预测了他莫昔芬治疗和非 - 治疗患者。编码RAS相关小G蛋白的ARHI基因的高水平启动子甲基化被证明是没有接受他莫昔芬治疗的患者更好的生存的优选预测因子。

7. 发明授权

US08367336B2 Association of the DNA methylation profile of the CYP1B1 gene with response to adjuvant therapy in breast cancer 有权
标题翻译： CYP1B1基因DNA甲基化谱与乳腺癌辅助治疗反应的关系
公开(公告)号：US08367336B2
公开(公告)日：2013-02-05
申请号：US11628390
申请日：2005-06-01
申请人： Martin Widschwendter , Kimberly D. Siegmund , Peter A. Jones , Peter W. Laird
发明人： Martin Widschwendter , Kimberly D. Siegmund , Peter A. Jones , Peter W. Laird
IPC分类号： C12Q1/68 , C12P19/34
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/118 , C12Q2600/154
摘要： Particular embodiments provide novel and clinically useful DNA methylation predictors of hormone receptor status, and predictors of response to endocrine (e.g., hormonal) and non-endocrine breast cancer therapy. The ESR1 gene, encoding the estrogen receptor (ER) alpha proved to be the preferred predictor of progesterone receptor (PR) status, while methylation of the PGR gene, encoding PR, was the preferred predictor of ER status. ESR1 methylation outperformed hormone receptor status as a predictor of clinical response in patients treated with antiestroges (e.g., tamoxifen), while promoter methylation of the CYP1B1 gene, encoding a tamoxifen and estradiol metabolizing cytochrome P450, predicted response differentially in tamoxifen-treated and non-treated patients. High levels of promoter methylation of the ARH1 gene, encoding a RAS-related small G-protein, were shown to be preferred predictors of better survival in patients who had not received tamoxifen therapy.
摘要翻译：具体实施方案提供了激素受体状态的新型和临床有用的DNA甲基化预测因子，以及对内分泌（例如激素）和非内分泌乳腺癌治疗的预测因子。编码雌激素受体（ER）α的ESR1基因被证明是孕酮受体（PR）状态的优选预测因子，而编码PR的PGR基因的甲基化是ER状态的优选预测因子。 ESR1甲基化优于激素受体状态，作为抗前列腺治疗患者临床反应的预测因子（如他莫昔芬），而CYP1B1基因的启动子甲基化，编码他莫昔芬和雌二醇代谢细胞色素P450，预测了他莫昔芬治疗和非 - 治疗患者。编码RAS相关小G蛋白的ARH1基因的高水平启动子甲基化被证明是没有接受他莫昔芬治疗的患者更好的生存的优选预测因子。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式